




RealRate

PHARMACEUTICAL 2022

Inozyme Pharma Inc
Rank 153 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Inozyme Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Inozyme Pharma Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 93% points. The greatest weakness of Inozyme Pharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 344%, being 69% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	115,342
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,633
Liabilities, Non-Current	2,640
Other Assets	5,816
Other Compr. Net Income	16
Other Expenses	0
Other Liabilities	0
Other Net Income	22
Other Revenues	0
Property and Equipment	2,383
Research and Development	37,720
Selling, General and Administrative Expense	18,926

Output Variable	Value in 1000 USD
Assets	123,541
Liabilities	14,273
Expenses	56,646
Revenues	0
Stockholders Equity	109,268
Net Income	-56,624
Comprehensive Net Income	-56,616
BaseVar	97,249
ECR before LimitedLiability	264%
Economic Capital Ratio	344%